Roche’s Evrysdi offers sustained benefits in SMA extension trial in children

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jun 10, 2024 at 11:12: AM
via Roche has announced five-year findings from the open-label extension portion of the FIREFISH study, where Evrysdi (risdiplam) offered sustained efficacy and safety in children with type 1 spinal muscular atrophy (SMA).

article source
 

<



Similar threads

cafead
Roche’s spinal muscular atrophy treatment Evrysdi shows continued benefit in children
Replies
0
Views
15
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Roche&#039;s aim to widen Evrysdi&#039;s label nabs speedy FDA review in young spinal...
Replies
0
Views
147
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Roche builds evidence for Evrysdi’s benefits in younger SMA patients
Replies
0
Views
150
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Citing &#039;less-than-optimal&#039; outcomes for Roche&#039;s Evrysdi, Biogen launches...
Replies
0
Views
168
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Evrysdi has ‘real world impact’ on lives of babies with severe SMA, says Roche
Replies
0
Views
191
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote